The role of monoamine oxidase inhibitors in depression treatment guidelines

J Clin Psychiatry. 2012;73 Suppl 1:10-6. doi: 10.4088/JCP.11096su1c.02.

Abstract

Monoamine oxidase inhibitors (MAOIs) have proven efficacy for treating depression and for decades have been a preferred treatment for patients with atypical depression, high levels of anxiety, anergic bipolar depression, and treatment-resistant depression. However, MAOIs are infrequently used due to safety and tolerability concerns and the need for dietary restrictions. Current guidelines, which are reviewed here, recommend MAOIs as third-, fourth-, or fifth-line treatments due to these concerns. However, a transdermal formulation of selegiline limits the need for dietary restrictions and has fewer side effects than many more widely used antidepressants. The availability of a safer and more tolerable formulation gives clinicians another option in their armamentarium for treating depression.

Publication types

  • Comparative Study

MeSH terms

  • Administration, Cutaneous
  • Administration, Oral
  • Antidepressive Agents / administration & dosage*
  • Antidepressive Agents / adverse effects
  • Cross-Cultural Comparison
  • Depressive Disorder / diagnosis
  • Depressive Disorder / drug therapy*
  • Depressive Disorder / psychology
  • Depressive Disorder, Major / diagnosis
  • Depressive Disorder, Major / drug therapy
  • Depressive Disorder, Major / psychology
  • Dose-Response Relationship, Drug
  • Drug Interactions
  • Drug Therapy, Combination
  • Food-Drug Interactions
  • General Practice
  • Humans
  • Monoamine Oxidase Inhibitors / administration & dosage*
  • Monoamine Oxidase Inhibitors / adverse effects
  • Practice Guidelines as Topic
  • Referral and Consultation
  • Risk Factors
  • Secondary Prevention
  • Treatment Outcome

Substances

  • Antidepressive Agents
  • Monoamine Oxidase Inhibitors